U.S. Bioscience, Beaufour Ipsen deal

Beaufour Ipsen (Paris) will market in Europe UBS's Hexalen (altretamine) and NeuTrexin (trimetrexate glucuronate). NeuTrexin has approvals in France, Germany, Ireland, Luxembourg, the Netherlands and the U.K. to treat Pneumocystis carinii pneumonia. Hexalen is approved for sale in the U.K. to treat ovarian cancer. ...